Page last updated: 2024-10-22

amlodipine and Headache

amlodipine has been researched along with Headache in 30 studies

Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.

Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.

Research Excerpts

ExcerptRelevanceReference
"This 8-week study in Korea aimed to evaluate the efficacy and tolerability of a telmisartan/amlodipine + hydrochlorothiazide (TAH) combination versus telmisartan/amlodipine (TA) combination in patients with essential hypertension that did not respond appropriately to 4-week treatment with TA."9.27Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St ( Ahn, JC; Ahn, JH; Ahn, YK; Cha, DH; Chae, IH; Cho, DK; Cho, SK; Choi, YJ; Hong, SJ; Hong, TJ; Hyon, MS; Jang, JY; Jeon, DW; Jeong, JO; Kim, BS; Kim, HS; Kim, SH; Nam, CW; Oh, YS; Park, SH; Rha, SW; Song, JM; Sung, KC; Won, KH; Yang, TH; Yoo, BS; Yoo, KD; Yoon, YW, 2018)
"The objective of this study was to evaluate the efficacy and safety of a fimasartan/amlodipine combination in patients with hypertension and to determine the optimal composition for a future single-pill combination formulation."9.20A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension. ( Ahn, T; Ahn, Y; Bae Park, J; Cho, EJ; Choi, DJ; Chull Chae, S; Chun, KJ; Han, KR; Hyon, MS; Jeon, ES; Jeong, JO; Joo, SJ; Kim, DI; Kim, DS; Kim, JJ; Kim, KS; Kim, YJ; Kwan, J; Lee, HY; Oh, SK; Park, JS; Rhee, MY; Seog Seo, H; Shin, JH; Sung, KC; Yoo, BS; Youn, HJ, 2015)
" The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy."9.15Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. ( Ferdinand, KC; Pool, J; Purkayastha, D; Townsend, R; Weitzman, R, 2011)
"Eight weeks of treatment with amlodipine adipate produced significant reductions from baseline in blood pressure in these patients with mild to moderate hypertension."9.11Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison. ( Chong-Yun, R; Heung-Sun, K; Jin-Ok, J; Joo, SJ; Joon-Han, S; Ju, AK; Kang, HJ; Kang, JH; Kim, KS; Kim, MH; Koo, BK; Lee, HY; Lim, DK; Oh, BH; Park, KM; Park, SH; Park, SY; Ro, YM; Seo, HS; Woong, CJ; Yeon, KJ; Yoon, J, 2005)
"The antihypertensive efficacy of nebivolol and amlodipine and their tolerability were compared in a multicentre, randomized, active-controlled, double-blind parallel-group trial in elderly patients with mild to moderate essential arterial hypertension."9.10Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. ( Gil-Extremera, B; Maldonato, A; Mazza, A; Pessina, AC; Toutouzas, T, 2002)
"Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure."9.10Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003)
"One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks."9.08Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. ( Bodin, F; Cardoni, O; Corea, L; Fogari, R; Innocenti, P; Meilenbrock, S; Porcellati, C; Provvidenza, M; Sullivan, J, 1996)
"The present study aimed to assess the efficacy and tolerance of amlodipine (Norvasc-Pfizer) in the treatment of 152 patients with mild and moderate essential hypertension."9.08-Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-. ( Kokot, F; Kokot, M; Raszewska, J; Rychlik, G; Witkowicz, J, 1995)
"5-10 mg) once daily was compared with atenolol (50-100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study."9.07Amlodipine versus atenolol in essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1994)
"Although risks of peripheral edema are three-fold higher on amlodipine, up to one-third of edema cases on amlodipine might not be induced by amlodipine."9.01Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. ( Böhm, M; Mahfoud, F; Messerli, FH; Scholz, SS; Vukadinović, D; Weber, MA; Williams, B, 2019)
" Both treatment groups had similar adverse event rates (35."6.76Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. ( Black, HR; Hilkert, R; Israel, M; Izzo, J; Lee, J; Purkayastha, D; Sridharan, K; Weinberger, MH, 2011)
" Most adverse events were mild or moderate and the investigators' overall evaluation of tolerability was excellent or good for 91% of patients."6.67A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice. ( Varrone, J, 1991)
"This 8-week study in Korea aimed to evaluate the efficacy and tolerability of a telmisartan/amlodipine + hydrochlorothiazide (TAH) combination versus telmisartan/amlodipine (TA) combination in patients with essential hypertension that did not respond appropriately to 4-week treatment with TA."5.27Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St ( Ahn, JC; Ahn, JH; Ahn, YK; Cha, DH; Chae, IH; Cho, DK; Cho, SK; Choi, YJ; Hong, SJ; Hong, TJ; Hyon, MS; Jang, JY; Jeon, DW; Jeong, JO; Kim, BS; Kim, HS; Kim, SH; Nam, CW; Oh, YS; Park, SH; Rha, SW; Song, JM; Sung, KC; Won, KH; Yang, TH; Yoo, BS; Yoo, KD; Yoon, YW, 2018)
"The objective of this study was to evaluate the efficacy and safety of a fimasartan/amlodipine combination in patients with hypertension and to determine the optimal composition for a future single-pill combination formulation."5.20A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension. ( Ahn, T; Ahn, Y; Bae Park, J; Cho, EJ; Choi, DJ; Chull Chae, S; Chun, KJ; Han, KR; Hyon, MS; Jeon, ES; Jeong, JO; Joo, SJ; Kim, DI; Kim, DS; Kim, JJ; Kim, KS; Kim, YJ; Kwan, J; Lee, HY; Oh, SK; Park, JS; Rhee, MY; Seog Seo, H; Shin, JH; Sung, KC; Yoo, BS; Youn, HJ, 2015)
" The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy."5.15Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. ( Ferdinand, KC; Pool, J; Purkayastha, D; Townsend, R; Weitzman, R, 2011)
"In these adult patients with mild to moderate hypertension, the combination of amlodipine + valsartan was associated with significantly greater blood pressure reductions from baseline compared with amlodipine or valsartan monotherapy or placebo."5.12Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hyperten ( Glazer, R; Jin, J; Philipp, T; Pospiech, R; Schneider, H; Smith, TR; Wernsing, M; Yen, J, 2007)
"The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension."5.12Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stag ( Bagchi, A; Baliga, VP; Bollmall, C; Kinagi, SB; Sharma, A; Sharma, YK, 2007)
"Eight weeks of treatment with amlodipine adipate produced significant reductions from baseline in blood pressure in these patients with mild to moderate hypertension."5.11Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison. ( Chong-Yun, R; Heung-Sun, K; Jin-Ok, J; Joo, SJ; Joon-Han, S; Ju, AK; Kang, HJ; Kang, JH; Kim, KS; Kim, MH; Koo, BK; Lee, HY; Lim, DK; Oh, BH; Park, KM; Park, SH; Park, SY; Ro, YM; Seo, HS; Woong, CJ; Yeon, KJ; Yoon, J, 2005)
"Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure."5.10Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003)
"The antihypertensive efficacy of nebivolol and amlodipine and their tolerability were compared in a multicentre, randomized, active-controlled, double-blind parallel-group trial in elderly patients with mild to moderate essential arterial hypertension."5.10Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. ( Gil-Extremera, B; Maldonato, A; Mazza, A; Pessina, AC; Toutouzas, T, 2002)
"The present study aimed to assess the efficacy and tolerance of amlodipine (Norvasc-Pfizer) in the treatment of 152 patients with mild and moderate essential hypertension."5.08-Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-. ( Kokot, F; Kokot, M; Raszewska, J; Rychlik, G; Witkowicz, J, 1995)
"One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks."5.08Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. ( Bodin, F; Cardoni, O; Corea, L; Fogari, R; Innocenti, P; Meilenbrock, S; Porcellati, C; Provvidenza, M; Sullivan, J, 1996)
"5-10 mg) once daily was compared with atenolol (50-100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study."5.07Amlodipine versus atenolol in essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1994)
"In a multicentre crossover study of 97 patients with mild hypertension, the incidence and severity of adverse effects were observed during the first 14 days of treatment with amlodipine, nifedipine retard or placebo."5.07Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard. ( Bremner, AD; Fell, PJ; Hosie, J; James, IG; Saul, PA; Taylor, SH, 1993)
"The effects of amlodipine on ambulatory blood pressure were investigated in patients with mild-to-moderate hypertension."5.07A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure. ( Burris, JF; Klein, J; Mroczek, WJ, 1991)
"Although risks of peripheral edema are three-fold higher on amlodipine, up to one-third of edema cases on amlodipine might not be induced by amlodipine."5.01Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. ( Böhm, M; Mahfoud, F; Messerli, FH; Scholz, SS; Vukadinović, D; Weber, MA; Williams, B, 2019)
"the Indonesian subset of the EXCITE (clinical EXperience of amlodIpine and valsarTan in hypErtension) study, which was a multinational, prospective, observational, open study in hypertensive patients treated with Aml/Val SPC for 26 weeks."3.81Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study. ( Abdillah, A; Kalim, H; Setiawati, A, 2015)
" Both treatment groups had similar adverse event rates (35."2.76Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. ( Black, HR; Hilkert, R; Israel, M; Izzo, J; Lee, J; Purkayastha, D; Sridharan, K; Weinberger, MH, 2011)
"We conducted 3 open-label, multiple-dose, 3-period, randomized, crossover studies in healthy subjects to assess the potential pharmacokinetic interaction between vildagliptin, a novel dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, and representatives of 3 commonly prescribed antihypertensive drug classes: (1) the calcium channel blocker, amlodipine; (2) the angiotensin receptor blocker, valsartan; and (3) the angiotensin-converting enzyme inhibitor, ramipril."2.73Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. ( Campestrini, J; Dole, K; Dole, WP; He, YL; Howard, D; Ligueros-Saylan, M; Marion, A; Pommier, F; Sabo, R; Sunkara, G; Wang, Y; Zhao, C, 2008)
"The primary aim of this double-blind, parallel group trial was to compare incidence of newly occurring vasodilatory adverse events in elderly patients treated with recommended once-daily doses of felodipine extended release (ER) or amlodipine."2.69Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. ( Aldons, PM; Burgess, ED; Girerd, X; Morgan, TO; Rehn, L; Schaefer, RM; Singh, GP; Tilvis, R, 1998)
" Neither AUC nor trough levels of FEL and AML were significantly influenced by transit times, nor was Cmax after any of the three treatments."2.69The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ( Laufen, H; Riedel, KD; Scharpf, F; Schumacher, T; Yeates, R; Zimmermann, T, 1999)
" Most adverse events were mild or moderate and the investigators' overall evaluation of tolerability was excellent or good for 91% of patients."2.67A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice. ( Varrone, J, 1991)
"Aggressive treatment of hypertension resulted in complete resolution of the clinical and radiologic features of the syndrome."1.43Does this patient have hypertensive encephalopathy? ( Argyropoulou, MI; Christopoulou, F; Elisaf, M; Kosta, P; Rizos, EC, 2016)

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's8 (26.67)18.2507
2000's9 (30.00)29.6817
2010's10 (33.33)24.3611
2020's3 (10.00)2.80

Authors

AuthorsStudies
Konan, ML1
Tokpa, A1
Okamon, M1
Wilfried, M1
N'gassa, A1
Brou, J1
Djondé, G1
Oka, DN1
Roffey, E1
Bhurawala, H1
Jafari, R1
Rostami, Z1
Nikpoor, M1
Javanbakht, M1
Ghahroudi, MS1
Hosseini, MS1
Einollahi, B1
Reid, HW1
Moorthy, G1
Clark, D1
Cannon, L1
Ming, DY1
Sung, KC2
Oh, YS1
Cha, DH1
Hong, SJ1
Won, KH1
Yoo, KD1
Rha, SW1
Ahn, YK1
Ahn, JC1
Jang, JY1
Hong, TJ1
Cho, SK1
Park, SH2
Hyon, MS2
Nam, CW1
Chae, IH1
Yoo, BS2
Song, JM1
Jeong, JO2
Yoon, YW1
Kim, BS1
Yang, TH1
Cho, DK1
Kim, SH1
Choi, YJ1
Ahn, JH1
Jeon, DW1
Kim, HS1
Tsuchida, T1
Yano, H1
Raita, Y1
Kinjo, M1
Tafoya, C1
Singh, A1
Vukadinović, D1
Scholz, SS1
Messerli, FH1
Weber, MA2
Williams, B1
Böhm, M1
Mahfoud, F1
Lee, HY2
Kim, YJ1
Ahn, T1
Youn, HJ1
Chull Chae, S1
Seog Seo, H1
Kim, KS2
Rhee, MY1
Choi, DJ1
Kim, JJ1
Chun, KJ1
Park, JS1
Oh, SK1
Kim, DS1
Kwan, J1
Ahn, Y1
Bae Park, J1
Cho, EJ1
Han, KR1
Kim, DI1
Joo, SJ2
Shin, JH1
Jeon, ES1
Setiawati, A1
Kalim, H1
Abdillah, A1
Christopoulou, F1
Rizos, EC1
Kosta, P1
Argyropoulou, MI1
Elisaf, M1
Castelino, FV1
Wasfy, JH1
Collier, D1
Ferdinand, KC1
Pool, J1
Weitzman, R1
Purkayastha, D2
Townsend, R1
Black, HR1
Weinberger, MH1
Lee, J1
Sridharan, K1
Israel, M1
Hilkert, R1
Izzo, J1
Mazza, A1
Gil-Extremera, B1
Maldonato, A1
Toutouzas, T1
Pessina, AC1
White, WB1
Duprez, D1
St Hillaire, R1
Krause, S1
Roniker, B1
Kuse-Hamilton, J1
Kang, HJ1
Koo, BK1
Oh, BH1
Heung-Sun, K1
Seo, HS1
Ro, YM1
Kang, JH1
Woong, CJ1
Kim, MH1
Joon-Han, S1
Yoon, J1
Jin-Ok, J1
Ju, AK1
Chong-Yun, R1
Yeon, KJ1
Park, KM1
Lim, DK1
Park, SY1
Chung, M1
Calcagni, A1
Glue, P1
Bramson, C1
Philipp, T1
Smith, TR1
Glazer, R1
Wernsing, M1
Yen, J1
Jin, J1
Schneider, H1
Pospiech, R1
He, YL1
Ligueros-Saylan, M1
Sunkara, G1
Sabo, R1
Zhao, C1
Wang, Y1
Campestrini, J1
Pommier, F1
Dole, K1
Marion, A1
Dole, WP1
Howard, D1
Sharma, A1
Bagchi, A1
Kinagi, SB1
Sharma, YK1
Baliga, VP1
Bollmall, C1
Frishman, WH1
Brobyn, R1
Brown, RD1
Johnson, BF1
Reeves, RL1
Wombolt, DG1
Bremner, AD1
Fell, PJ1
Hosie, J1
James, IG1
Saul, PA1
Taylor, SH1
Kokot, F1
Witkowicz, J1
Kokot, M1
Rychlik, G1
Raszewska, J1
Corea, L1
Cardoni, O1
Fogari, R1
Innocenti, P1
Porcellati, C1
Provvidenza, M1
Meilenbrock, S1
Sullivan, J1
Bodin, F1
Schaefer, RM1
Aldons, PM1
Burgess, ED1
Tilvis, R1
Girerd, X1
Singh, GP1
Rehn, L1
Morgan, TO1
Zimmermann, T1
Laufen, H1
Yeates, R1
Scharpf, F1
Riedel, KD1
Schumacher, T1
Hall, R1
Chong, C1
Mroczek, WJ1
Burris, JF1
Klein, J1
Varrone, J1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by[NCT02738632]Phase 3300 participants (Anticipated)Interventional2015-05-31Completed
[NCT01518998]Phase 2420 participants (Actual)Interventional2011-08-31Completed
An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension[NCT00739596]Phase 4332 participants (Actual)Interventional2008-07-31Completed
Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761]Phase 4471 participants (Actual)Interventional2018-02-13Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants Achieving BP Control After 8 Weeks of Treatment

To compare the percentage of patients achieving BP control (<140/90 mm Hg) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: 8 weeks

InterventionCumulative percentage of participants (Number)
Aliskiren HCTZ63.6
Amlodipine62.3

Percentage of Responders After 8 Weeks of Treatment.

To compare the percentage of responders after 8 weeks of treatment with an aliskiren HCTZ based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension: [ Responders were defined as patients with MSSBP < 140 mm Hg or a decrease from baseline ≥ 20 mm Hg at 1st response. A response was counted when a patient first achieved MSSBP < 140 mm Hg or a decrease from baseline ≥ 20 mm Hg.] (NCT00739596)
Timeframe: 8 weeks

InterventionCumulative percentage of responders (Number)
Aliskiren HCTZ84.6
Amlodipine90.7

Change in Mean Sitting Diastolic Blood Pressure (MSDBP) After 8 Weeks of Treatment

To assess the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks

,
Interventionmm Hg (Mean)
BaselineWeek 8Change from Baseline to Week 8
Aliskiren HCTZ96.086.0-10.0
Amlodipine95.084.0-11.0

Change in Mean Sitting Pulse Pressure (MSPP) After 8 Weeks of Treatment

To compare the change from baseline in mean sitting pulse pressure (MSPP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks

,
Interventionmm Hg (Mean)
BaselineWeek 8Change from Baseline to Week 8
Aliskiren HCTZ72.252.7-19.4
Amlodipine73.155.1-18.0

Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment

To assess the change from baseline in MSSBP after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks

,
Interventionmm Hg (Mean)
BaselineWeek 8Change from baseline to Week 8
Aliskiren HCTZ168.2138.8-29.4
Amlodipine168.1139.1-29.0

Reviews

2 reviews available for amlodipine and Headache

ArticleYear
Cardiac Memory: A Case Report and Review of the Literature.
    The Journal of emergency medicine, 2019, Volume: 57, Issue:1

    Topics: Aged; Amlodipine; Arrhythmias, Cardiac; Aspirin; Bundle-Branch Block; Chest Pain; Electrocardiograph

2019
Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials.
    Journal of hypertension, 2019, Volume: 37, Issue:10

    Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Edema; Headache; Humans; Hypertension

2019

Trials

20 trials available for amlodipine and Headache

ArticleYear
Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St
    Clinical therapeutics, 2018, Volume: 40, Issue:1

    Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Dizzine

2018
A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension.
    Clinical therapeutics, 2015, Nov-01, Volume: 37, Issue:11

    Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind M

2015
Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial.
    Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:5

    Topics: Adult; Amides; Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Brach

2011
Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension.
    Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:8

    Topics: Adult; Amides; Amlodipine; Black or African American; Blood Pressure; Blood Pressure Monitoring, Amb

2011
Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly.
    Blood pressure, 2002, Volume: 11, Issue:3

    Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzopyrans; Blood Pressure; Double-Bl

2002
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    Hypertension (Dallas, Tex. : 1979), 2003, Volume: 41, Issue:5

    Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channe

2003
Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison.
    Clinical therapeutics, 2005, Volume: 27, Issue:6

    Topics: Adipates; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Capsules; Double-Blind M

2005
Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet.
    Journal of clinical pharmacology, 2006, Volume: 46, Issue:10

    Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Area Under Curve; Atorvastatin

2006
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hyperten
    Clinical therapeutics, 2007, Volume: 29, Issue:4

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Double-Blind Method;

2007
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    Journal of clinical pharmacology, 2008, Volume: 48, Issue:1

    Topics: Adamantane; Administration, Oral; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiot

2008
Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stag
    Clinical therapeutics, 2007, Volume: 29, Issue:12

    Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzo

2007
Amlodipine versus atenolol in essential hypertension.
    The American journal of cardiology, 1994, Jan-27, Volume: 73, Issue:3

    Topics: Adolescent; Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Double-Blind Method; Drug Administrat

1994
Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard.
    Journal of human hypertension, 1993, Volume: 7, Issue:1

    Topics: Adult; Aged; Amlodipine; Delayed-Action Preparations; Dizziness; Double-Blind Method; Edema; Female;

1993
-Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-.
    Polskie Archiwum Medycyny Wewnetrznej, 1995, Volume: 94, Issue:4

    Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Dizziness; Drug Administration Schedule; Edema; Fe

1995
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
    Clinical pharmacology and therapeutics, 1996, Volume: 60, Issue:3

    Topics: Adult; Aged; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents;

1996
Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group.
    International journal of clinical practice, 1998, Volume: 52, Issue:6

    Topics: Aged; Amlodipine; Antihypertensive Agents; Delayed-Action Preparations; Dizziness; Double-Blind Meth

1998
The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times.
    Journal of clinical pharmacology, 1999, Volume: 39, Issue:10

    Topics: Adult; Amlodipine; Area Under Curve; Biological Availability; Calcium Channel Blockers; Cross-Over S

1999
A double-blind, parallel-group study of amlodipine versus long-acting nitrate in the management of elderly patients with stable angina.
    Cardiology, 2001, Volume: 96, Issue:2

    Topics: Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Dela

2001
A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure.
    Postgraduate medical journal, 1991, Volume: 67 Suppl 5

    Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Determination; Calcium Channel B

1991
A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice.
    Postgraduate medical journal, 1991, Volume: 67 Suppl 5

    Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Calcium Channel Blockers; Edema; Female; Headache; Human

1991

Other Studies

8 other studies available for amlodipine and Headache

ArticleYear
Multiple Cerebral Aneurysms Treated by Microsurgical and Endovascular Technique.
    World neurosurgery, 2022, Volume: 165

    Topics: Amlodipine; Aneurysm, Ruptured; Embolization, Therapeutic; Endovascular Procedures; Female; Headache

2022
The hypertensive child.
    Australian journal of general practice, 2019, Volume: 48, Issue:12

    Topics: Abdominal Pain; Adrenocorticotropic Hormone; Aldosterone; Amlodipine; Antihypertensive Agents; Catec

2019
Detection of significant left renal artery stenosis caused by fibromuscular dysplasia with selective angiography.
    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2020, Jan-14, Volume: 91, Issue:4

    Topics: Amlodipine; Angioplasty, Balloon; Antihypertensive Agents; Computed Tomography Angiography; Drug Com

2020
A Big Headache: An Unusual Case of Hypertensive Urgency in an Adolescent.
    Clinical pediatrics, 2021, Volume: 60, Issue:9-10

    Topics: Adolescent; Amlodipine; Antihypertensive Agents; Aorta, Abdominal; Aortic Valve Stenosis; Computed T

2021
Nephrotic range proteinuria and metabolic alkalosis in Takayasu arteritis.
    BMJ case reports, 2019, Apr-15, Volume: 12, Issue:4

    Topics: Adolescent; Alkalosis; Amlodipine; Antihypertensive Agents; Female; Glomerulosclerosis, Focal Segmen

2019
Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study.
    Acta medica Indonesiana, 2015, Volume: 47, Issue:3

    Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cough; Drug Combinations; Drug Sub

2015
Does this patient have hypertensive encephalopathy?
    Journal of the American Society of Hypertension : JASH, 2016, Volume: 10, Issue:5

    Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Brain; Carbazoles; Carvedilol; Computed Tom

2016
A 36-year-old man with paresthesias and a headache.
    Arthritis and rheumatism, 2008, Sep-15, Volume: 59, Issue:9

    Topics: Adult; Amlodipine; Biopsy; Diagnosis, Differential; Drug Therapy, Combination; Guanine; Headache; He

2008